Abstract
Respiratory syncytial virus (RSV), long recognised as the major viral pathogen of the lower respiratory tract of infants, has also been implicated in severe lung disease in adults, especially the elderly. This fact, and the demonstration that passive prophylaxis with either polyclonal or monoclonal antibody to RSV prevents severe lung disease in high-risk infants and children, has led to renewed interest in the immune mechanisms surrounding protection, and the development of vaccines
Publication types
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Adult
-
Aged
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Child
-
Child, Preschool
-
Humans
-
Infant
-
Palivizumab
-
Respiratory Syncytial Virus Infections* / diagnosis
-
Respiratory Syncytial Virus Infections* / epidemiology
-
Respiratory Syncytial Virus Infections* / immunology
-
Respiratory Syncytial Virus Infections* / therapy
-
Respiratory Syncytial Viruses / immunology
-
Viral Vaccines
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Viral Vaccines
-
Palivizumab